

Additional information regarding these materials is described in: Kamohara *et al.*, "Discoidin domain receptor 1 isoform-a (DDR1a) promotes migration of leukocytes in three-dimensional collagen lattices," *FASEB J.*, 15:2724-2726, 2001; Matsuyama *et al.*, "Interaction of discoidin receptor 1 isoform b (DDR1b) with collagen activates p38 mitogen-activated protein kinase and promotes differentiation of macrophages," *FASEB J.*, 17:1286-1288, 2003; Matsuyama *et al.*, "Activation of discoidin receptor 1 facilitates the maturation of human monocyte-derived dendritic cells through the TNF receptor associated factor 6/TGF-beta-activated protein kinase 1 binding protein 1beta/p38alpha mitogen-activated protein kinase signaling cascade," *J. Immunol.* 171:3520-3532, 2003; Matsuyama *et al.*, "Activation of discoidin domain receptor 1 isoform b with collagen up-regulates chemokine production in human macrophages: Role of p38 mitogen-activated protein kinase and NF-kB," *J. Immunol.* 172:2332-2340, 2004.

#### **Method for Ex-Vivo Selection and Expansion of Stimulus-Responding Primary Cells Using Selective Reversible Immortalization**

Eugene Barsov, David Ott (NCI)

*U.S. Provisional Application No.:* 60/528,244 filed 09 Dec 2003 (DHHS Reference No. E-210-2002/0-US-01).

*Licensing Contact:* Mojdeh Bahar; (301) 435-2950; [baharm@mail.nih.gov](mailto:baharm@mail.nih.gov).

This invention is a gene transfer technique to immortalize primary cells (e.g. lymphocytes) that respond to a stimulus, such as a viral antigen (e.g. HIV toxoids), a tumor antigen, or a growth factor. The antigen or growth factor stimulates a specific subset of primary cells within a population of cells to proliferate and divide. Murine leukemia virus (MuLV)-based retroviral vectors comprising a gene or genes for immortalization are used to transfect primary cells that have been stimulated to divide. Since MuLV retroviral vectors will only infect dividing cells, only primary cells activated by the antigen or growth factor will be infected by this retroviral vector and immortalized, thereby creating an "antigen-specific trap." The primary cells to be immortalized can be in targeted tissue or in stimulated *ex vivo* culture. The transduced cells are expanded to large numbers without differentiating, and brought back to the primary cell stage by removing the introduced genes (e.g. by Cre-lox recombination). The expanded population of primary cells can then be used.

#### **Hybrid Adeno-Retroviral Vector for the Transformation of Cells**

Changyu Zheng, Brian O'Connell, Bruce J. Baum (NIDCR)

*U.S. Provisional Application No.:* 60/265,198 filed 30 Jan 2001 (DHHS Reference No. E-312-2000/0-US-01; PCT Application PCT/US02/02279 filed 25 Jan 2002, which was published as WO 02/061104 on 30 Jul 2002 (DHHS Reference No. E-312-2000/0-PCT-02).

*U.S. Patent Application No.:* 10/470,784 filed 29 Jul 2003 (DHHS Reference No. E-312-2000/0-US-03).  
*Licensing Contact:* Jesse Kindra; (301) 435-5559; [kindraj@mail.nih.gov](mailto:kindraj@mail.nih.gov).

The invention described and claimed in these patent applications provides for novel hybrid vectors which may be used for cell transformation either *in vivo*, *in vitro*, or *ex vivo*. The hybrid vectors, which are capable of integrating into the chromosome of the host cell and are capable of transducing dividing and non-dividing cells, have an adenoviral serotype 5 backbone and two retroviral (Moloney murine leukemia virus) elements upstream and downstream of the transgene. These elements include part of the envelope sequence, the long terminal repeat (LTR) and the packaging signal sequence (upstream), and part of the envelope sequence and LTR (downstream). Due to their hybrid nature, these vectors provide a means of efficient, reliable, long-term gene expression. Furthermore, unlike other chimeric or hybrid vector systems, only a single vector is required to deliver a transgene of interest and retroviral functional proteins are not required. The vectors are packaged and delivered via an adenoviral particle and administered directly to the target cell.

This research is described, in part, in: Zheng *et al.*, "Inclusion of Moloney murine leukemia virus elements upstream of the transgene cassette in an E1-deleted adenovirus leads to an unusual genomic integration in epithelial cells," *Virology* 2003 313:460-72, 2003; Zheng *et al.*, "Integration efficiency of a hybrid adenoretroviral vector," *Biochem Biophys Res Commun.* 300:115-20, 2003; Zheng & Baum, "Long-term expression after infection by the hybrid vector AdLTR-luc is from integrated transgene," *Biochem Biophys Res Commun.* 291:34-40, 2002.

Dated: August 31, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04-20295 Filed 9-7-04; 8:45 am]

**BILLING CODE 4140-01-P**

#### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

##### **Public Health Service**

##### **National Institutes of Health**

#### **National Institute of Environmental Health Sciences; Notice of a Meeting of the Scientific Advisory Committee on Alternative Toxicological Methods**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) on October 20, 2004, at the U.S. Environmental Protection Agency (EPA), 109 TW Alexander Drive, Durham, NC (Building C, Room C111, Auditorium sections A. and B). The SACATM provides advice on the statutorily mandated duties of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the activities of the National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM).

The meeting is being held on October 20, 2004, from 8:30 a.m. until adjournment and is open to the public with attendance limited only by the space available. Individuals who plan to attend are strongly encouraged to register with the NTP Executive Secretary by October 13, 2004, in order to ensure access to the EPA campus (Dr. Kristina Thayer at the NTP Liaison and Scientific Review Office, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709; telephone: 919-541-5021; facsimile: 919-541-0295; or e-mail: [thayer@niehs.nih.gov](mailto:thayer@niehs.nih.gov)) or online on the NTP Web site (<http://ntp-server.niehs.nih.gov>) under "What's New." A map of the EPA campus, including visitor parking, is available at <http://www.epa.gov/rtp/transportation/parking/map.htm>. Please note that a photo ID is required to access the EPA campus.

Persons needing special assistance, such as sign language interpretation or other reasonable accommodation in order to attend, are asked to notify the NTP Executive Secretary at least seven business days in advance of the meeting (see contact information above).

#### **Agenda**

A preliminary agenda is provided below. A copy of the agenda, committee roster, and any additional information, when available, will be posted on the

NTP Web site (<http://ntp-server.niehs.nih.gov>) under "What's New" or available upon request to the NTP Executive Secretary (contact information provided above). Additional information about SACATM is available through the NICEATM/ICCVAM Web site (<http://iccvam.niehs.nih.gov>) under "Advisory Committee." Following the meeting, summary minutes will be prepared and available at this Web site and upon request to the NTP Liaison and Scientific Review Office (contact information above).

#### Preliminary Agenda

Scientific Advisory Committee on Alternative Toxicological Methods, October 20, 2004. U.S. Environmental Protection Agency, Building C, Room C111 (Auditorium sections A. and B), 109 TW Alexander Drive, Durham, NC 27709. (A photo ID is required to access the EPA campus.)

October 20, 2004

8:30 a.m.

- Call to Order and Introductions.
- Welcome and Remarks from the National Institute of Environmental Health Sciences (NIEHS) and the National Toxicology Program (NTP).
- Welcome and Remarks from the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Chair.
- Update on Activities of the National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and ICCVAM.
- Update on the European Center for the Validation of Alternative Methods (ECVAM) Workshop Recommendations and Validation Studies.
- Evaluation of the Under-Prediction Rate for the *In Vivo* Rabbit Dermal Irritation Test.
- Public Comment.
- Evaluation of the Under-Prediction Rate for the *In Vivo* Rabbit Occular Irritation Test.
- Public Comment.

12 p.m.

Lunch break (on your own, the EPA campus has a cafeteria).

1 p.m.

- ICCVAM Nominations.
- Public Comment.
- NTP Roadmap.
- Public Comment.
- ECVAM-ICCVAM-NICEATM Workshop on Validation of Toxicogenomic-Based Test Systems.
- General Discussion.

4:30 p.m. Adjourn

#### Public Comment Welcome

Public input at this meeting is invited and time is set aside for the presentation of public comments on any agenda topic. Each organization is allowed one time slot per agenda topic. At least 7 minutes will be allotted to each speaker, and if time permits, may be extended to 10 minutes. In order to facilitate planning for this meeting, persons wishing to make an oral presentation are asked to notify the NTP Executive Secretary (contact information above) by October 13, 2004, and to provide their name, affiliation, mailing address, phone, fax, e-mail, and sponsoring organization (if any). Registration to present oral public comments or to submit written comments can be completed online at the NTP Web site (<http://ntp-server.niehs.nih.gov>) under "What's New." Registration for oral comments will also be available on-site, although time allowed for presentation by on-site registrants may be less than that for pre-registered speakers and will be determined by the number of persons who register at the meeting.

Persons registering to make oral comments are asked, if possible, to provide a copy of their statement to the NTP Executive Secretary (contact information above) by October 13, 2004, to enable review by the SACATM and NIEHS/NTP staff prior to the meeting. Written statements can supplement and may expand the oral presentation. If registering on-site and reading from written text, please bring 40 copies of the statement for distribution to the SACATM and NIEHS/NTP staff and to supplement the record. Written comments received in response to this notice will be posted on the NTP Web site (<http://ntp-server.niehs.nih.gov>) under "What's New". Persons may also submit written comments in lieu of making oral comments. Written comments should be sent to the NTP Executive Secretary and received by October 13, 2004, to enable review by the SACATM and NIEHS/NTP staff prior to the meeting. Persons submitting written comments should include their name, affiliation, mailing address, phone, fax, e-mail, and sponsoring organization (if any) with the document.

#### Background

The SACATM was established January 9, 2002, to fulfill section 3(d) of Public Law 106-545, the ICCVAM Authorization Act of 2000 (42 U.S.C. 2851-3(d)) and is composed of scientists from the public and private sectors (**Federal Register**: March 13, 2002: vol. 67, no. 49, page 11358). The SACATM provides advice to the Director of the

NIEHS, the ICCVAM, and the NICEATM regarding statutorily mandated duties of the ICCVAM and activities of the NICEATM. The committee's charter is posted on the Web at <http://iccvam.niehs.nih.gov> under "Advisory Committee" and is available in hard copy upon request from the NTP Executive Secretary (contact information above). Information about NICEATM and ICCVAM activities can also be found at the NICEATM/ICCVAM Web site (<http://iccvam.niehs.nih.gov>) or by contacting the Director of NICEATM, Dr. William Stokes (telephone: 919-541-2384, or e-mail: [niceatm@niehs.nih.gov](mailto:niceatm@niehs.nih.gov)).

Dated: August 26, 2004.

**Samuel Wilson,**

*Deputy Director, National Institute of Environmental Health Sciences.*

[FR Doc. 04-20292 Filed 9-7-04; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### Office of the Secretary

#### Homeland Security Advisory Council

**AGENCY:** Office of the Secretary, Department of Homeland Security.

**ACTION:** Notice of Federal Advisory Committee meeting.

**SUMMARY:** The Homeland Security Advisory Council (HSAC) will hold its next meeting in Washington, DC on Wednesday, September 22, 2004. The HSAC will meet for purposes of (1) receiving reports from Senior Advisory Committees; (2) receiving briefings from DHS staff on Departmental initiatives; and (3) holding roundtable discussions with and among HSAC members.

This meeting will be partially closed; the open portions of the meeting for purposes of (1) above will be held at the U.S. Coast Guard Headquarters, 2100 Second Street, SW., Washington, DC, from 9:30 a.m. to 11:15 a.m. The closed portions of the meeting, for purposes of (2) and (3) above will be held at the U.S. Coast Guard Headquarters from 8:30 a.m. to 9:20 a.m. and from 11:30 a.m. to 3:30 p.m.

**Public Attendance:** A limited number of members of the public may register to attend the public session on a first-come, first-served basis per the procedures that follow. Security requires that any member of the public who wishes to attend the public session provide his or her name, social security number, and date of birth no later than 5 p.m., EST, Wednesday, September 15, 2004. Please provide the required